Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2021 | Sep. 10, 2021 | |
Details | ||
Registrant CIK | 0000886093 | |
Fiscal Year End | --12-31 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2021 | |
Document Transition Report | false | |
Entity File Number | 000-22744 | |
Entity Registrant Name | NUNZIA PHARMACEUTICAL COMPANY | |
Entity Incorporation, State or Country Code | UT | |
Entity Tax Identification Number | 87-0442090 | |
Entity Address, Address Line One | 1627 West 14th Street | |
Entity Address, City or Town | Long Beach | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 90813 | |
City Area Code | 714 | |
Local Phone Number | 609-9117 | |
Entity Current Reporting Status | No | |
Entity Interactive Data Current | No | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 256,119,578 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q2 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Current Assets | ||
Cash | $ 1,503 | $ 0 |
Prepaid expenses | 2,500 | 0 |
Total current assets | 4,003 | 0 |
Investment in related party common stock | 5,000 | 0 |
Total assets | 9,003 | 0 |
Current liabilities | ||
Accounts payable and accrued liabilities | 25,994 | 25,868 |
Related party advances | 36,690 | 10,536 |
Total current liabilities | 62,684 | 36,404 |
Stockholders' deficit | ||
Common stock payable | 9,036,650 | 9,040,400 |
Additional paid-in capital | 29,134 | 29,134 |
Retained deficit | (9,372,636) | (9,350,359) |
Total stockholders' deficit | (53,681) | (36,404) |
Total liabilities and stockholders' deficit | 9,003 | 0 |
Common Class A | ||
Stockholders' deficit | ||
Common Stock, Value, Issued | 253,120 | 244,370 |
Common Class B | ||
Stockholders' deficit | ||
Common Stock, Value, Issued | $ 51 | $ 51 |
CONSOLIDATED BALANCE SHEETS - P
CONSOLIDATED BALANCE SHEETS - Parenthetical - $ / shares | Jun. 30, 2021 | Dec. 31, 2020 |
Common Class A | ||
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 1,000,000,000 | 1,000,000,000 |
Common Stock, Shares, Issued | 253,119,578 | 244,369,578 |
Common Stock, Shares, Outstanding | 253,119,578 | 244,369,578 |
Common Class B | ||
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 100,000 | 100,000 |
Common Stock, Shares, Issued | 51,000 | 51,000 |
Common Stock, Shares, Outstanding | 51,000 | 51,000 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Details | ||||
Revenues | $ 0 | $ 0 | $ 0 | $ 0 |
Operating expense | ||||
General and Administrative Expense | 6,629 | 1,337 | 22,277 | 8,238 |
Total operating expense | 6,629 | 1,337 | 22,277 | 8,238 |
Loss from operations | (6,629) | (1,337) | (22,277) | (8,238) |
Net loss | $ (6,629) | $ (1,337) | $ (22,277) | $ (8,238) |
Basic and Diluted Loss per Common Share | $ 0 | $ 0 | $ 0 | $ 0 |
Weighted average number of common shares outstanding - basic and diluted | 284,820,578 | 284,820,578 | 284,820,578 | 284,799,345 |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($) | Common Stock Payable | Additional Paid-in Capital | Retained Earnings | Total | Common Class A | Common Class B |
Equity Balance at Dec. 31, 2019 | $ 50,000 | $ 26,886 | $ (334,032) | $ (22,575) | $ 234,520 | $ 51 |
Equity Balance, Shares at Dec. 31, 2019 | 234,519,578 | 51,000 | ||||
Net loss | 0 | 0 | (6,901) | (6,901) | $ 0 | $ 0 |
Equity Balance, Shares at Mar. 31, 2020 | 234,769,578 | 51,000 | ||||
Equity Balance at Mar. 31, 2020 | 50,000 | 29,134 | (340,933) | (26,978) | $ 234,770 | $ 51 |
Common stock issued for services | 0 | 2,248 | 0 | 2,498 | $ 250 | 0 |
Common stock issued for services | 250,000 | |||||
Equity Balance at Dec. 31, 2019 | 50,000 | 26,886 | (334,032) | (22,575) | $ 234,520 | $ 51 |
Equity Balance, Shares at Dec. 31, 2019 | 234,519,578 | 51,000 | ||||
Net loss | (8,238) | |||||
Equity Balance, Shares at Jun. 30, 2020 | 234,769,578 | 51,000 | ||||
Equity Balance at Jun. 30, 2020 | 50,000 | 29,134 | (342,270) | (28,315) | $ 234,770 | $ 51 |
Equity Balance at Mar. 31, 2020 | 50,000 | 29,134 | (340,933) | (26,978) | $ 234,770 | $ 51 |
Equity Balance, Shares at Mar. 31, 2020 | 234,769,578 | 51,000 | ||||
Net loss | 0 | 0 | (1,337) | (1,337) | $ 0 | $ 0 |
Equity Balance, Shares at Jun. 30, 2020 | 234,769,578 | 51,000 | ||||
Equity Balance at Jun. 30, 2020 | 50,000 | 29,134 | (342,270) | (28,315) | $ 234,770 | $ 51 |
Equity Balance at Dec. 31, 2020 | 9,040,400 | 29,134 | (9,350,359) | (36,404) | $ 244,370 | $ 51 |
Equity Balance, Shares at Dec. 31, 2020 | 244,369,578 | 51,000 | ||||
Net loss | 0 | 0 | (15,648) | (15,648) | $ 0 | $ 0 |
Equity Balance, Shares at Mar. 31, 2021 | 244,369,578 | 51,000 | ||||
Equity Balance at Mar. 31, 2021 | 9,040,400 | 29,134 | (9,366,007) | (52,052) | $ 244,370 | $ 51 |
Equity Balance at Dec. 31, 2020 | 9,040,400 | 29,134 | (9,350,359) | (36,404) | $ 244,370 | $ 51 |
Equity Balance, Shares at Dec. 31, 2020 | 244,369,578 | 51,000 | ||||
Net loss | (22,277) | |||||
Equity Balance, Shares at Jun. 30, 2021 | 253,119,578 | 51,000 | ||||
Equity Balance at Jun. 30, 2021 | 9,036,650 | 29,134 | (9,372,636) | (53,681) | $ 253,120 | $ 51 |
Equity Balance at Mar. 31, 2021 | 9,040,400 | 29,134 | (9,366,007) | (52,052) | $ 244,370 | $ 51 |
Equity Balance, Shares at Mar. 31, 2021 | 244,369,578 | 51,000 | ||||
Merger shares issued | (17,750) | 0 | 0 | 0 | $ 17,750 | $ 0 |
Merger shares issued | 17,750,000 | |||||
Shares issued and received under Mutual Sales and Marketing Agreement | 5,000 | 0 | 0 | 5,000 | $ 0 | 0 |
Returned Merger shares previously issued in error in August 2020 | 9,000 | 0 | 0 | 0 | $ 9,000 | 0 |
Returned Merger shares previously issued in error in August 2020 | (9,000,000) | |||||
Returned Merger shares previously issued in error in August 2020 | (9,000) | 0 | 0 | 0 | $ (9,000) | 0 |
Net loss | 0 | 0 | (6,629) | (6,629) | $ 0 | $ 0 |
Equity Balance, Shares at Jun. 30, 2021 | 253,119,578 | 51,000 | ||||
Equity Balance at Jun. 30, 2021 | $ 9,036,650 | $ 29,134 | $ (9,372,636) | $ (53,681) | $ 253,120 | $ 51 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Cash flows from operating activities | ||
Net loss | $ (22,277) | $ (8,238) |
Adjustments to reconcile net loss to net cash flows from operating activities | ||
Stock based compensation expense | 0 | 2,498 |
Changes in operating assets and liabilities: | ||
Increase (Decrease) in Prepaid Expense | (2,500) | 0 |
Increase (decrease) in accounts payable and accrued expenses | 126 | 1,446 |
Increase (Decrease) in Due to Related Parties, Current | 26,154 | 4,294 |
Net cash flows from operating activities | 1,503 | 0 |
Change in cash | 1,503 | 0 |
Cash at beginning of period | 0 | 0 |
Cash at end of period | 1,503 | 0 |
Supplemental disclosure of cash flow information: | ||
Interest paid in cash | 0 | 0 |
Income taxes paid in cash | 0 | 0 |
Supplemental disclosure of non-cash transactions: | ||
Common stock issued as payment for liabilities | $ 0 | $ 2,498 |
NOTE 1 -Basis of Presentation,
NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements | 6 Months Ended |
Jun. 30, 2021 | |
Notes | |
NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements | NOTE 1 –Basis of Presentation, Organization , Going Concern and Recent Accounting Pronouncements Basis of Presentation The accompanying unaudited interim consolidated financial statements of Nunzia Pharmaceutical Company (the “ Company The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results may differ from those estimates. The interim financial statements should be read in conjunction with the unaudited financial statements and notes thereto included in the Company’s Annual Report for the year ended December 31, 2020. In the opinion of management, the accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) necessary for the fair presentation of the Company’s financial position as of June 30, 2021, results of operations for the three and six months ended June 30, 2021 and 2020, stockholders equity for the three and six months ended June 30, 2021 and 2020, and cash flows for the six months ended June 30, 2021 and 2020. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year. Organization Our Company’s name is Nunzia Pharmaceutical Company. The Company was incorporated on November 12, 1986. On February 1, 2018, the Company amended its Articles of Incorporation to change its name to Nunzia Pharmaceutical Corporation. On October 22, 2017, the Company and Cal-Biotech, Inc. (“ Cal-Biotech MCA MCA Shares LionsGate Prior to the close of the MCA, LionsGate held a majority beneficial ownership interest in the Company and Cal-Biotech. Thus, due to the common control of the Company and Cal-Biotech, pursuant to ASC 805-50-25, “Transactions Between Entities Under Common Control”, the MCA was accounted for as a transfer of the carrying amounts of assets and liabilities under the predecessor value method of accounting. The predecessor values method of accounting requires the receiving entity (i.e., the Company) to report the results of operations as if both entities had been combined as of the beginning of the periods presented. The consolidated financial statements above include both entities’ full results, including the financial statements of Cal-Biotech since inception on February 7, 2018. Going Concern The Company’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as a going concern. As of June 30, 2021, the Company had an accumulated deficit of $(9,372,636) The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. In view of these conditions, the ability of the Company to continue as a going concern is in doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. Historically, the Company has relied upon internally generated funds and funds from the sale of shares of stock, issuance of promissory notes and loans from its shareholders and private investors to finance its operations and growth. Management is planning to raise necessary additional funds for working capital through loans and/or additional sales of its common stock. However, there is no assurance that the Company will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should the Company be unable to raise this amount of capital its operating plans will be limited to the amount of capital that it can access. These financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying financial statements. Recent accounting pronouncements not yet adopted In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes. The guidance removes certain exceptions for recognizing deferred taxes for equity method investments, performing intra period allocation, and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for goodwill and allocating taxes to members of a consolidated group, among others. This guidance is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The transition requirements are dependent upon each amendment within this update and will be applied either prospectively or retrospectively. The adoption of ASU 2019-12 is not expected to have a material impact on the Company’s consolidated financial position, results of operations, or cash flows. Recently adopted accounting pronouncements The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the consolidated financial statements. |
NOTE 2 - Preferred and Common S
NOTE 2 - Preferred and Common Stock | 6 Months Ended |
Jun. 30, 2021 | |
Notes | |
NOTE 2 - Preferred and Common Stock | NOTE 2 – Preferred and Common Stock Preferred Stock The Company has Preferred stock: $1.00 par value; 50,000,000 shares authorized with no shares issued and outstanding. Common Stock The Company has 51,000 shares of Class B Common Stock issued and outstanding as of June 30, 2021. The Class B shares are the only shares eligible to vote for Directors. LionsGate holds all Class B common shares. The Company has 1,000,000,000 shares of Class A Common Stock authorized of which 253,119,578 and 234,519,578 shares are issued and outstanding as of June 30, 2021 and December 31, 2020, respectively. 31,650,000 MCA Shares due to LionsGate and 5,000,000 shares due to Global Whole Health Partners pursuant to the Mutual Sales and Marketing Agreement dated April 12, 2021 have not been issued as of June 30, 2021. On April 26, 2021, the Company issued 17,750,000 MCA Shares and on June 7, 2021, 9,000,000 MCA Shares originally issued in error on August 16, 2020, were returned to the Company bringing the total unissued MCA Shares to 31,650,000. On April 12, 2021, the Company and Global Whole Health Partners Corp. (“ Global MSMA |
NOTE 3 - Commitments and Contin
NOTE 3 - Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2021 | |
Notes | |
NOTE 3 - Commitments and Contingencies | NOTE 3 – Commitments and Contingencies COVID-19 In December 2019, an outbreak of the COVID-19 virus was reported in Wuhan, China. On March 11, 2020, the World Health Organization declared the COVID-19 virus a global pandemic and on March 13, 2020, President Donald J. Trump declared the virus a national emergency in the United States. This highly contagious disease has spread to most of the countries in the world and throughout the United States, creating a serious impact on customers, workforces and suppliers, disrupting economies and financial markets, and potentially leading to a world-wide economic downturn. It has caused a disruption of the normal operations of many businesses, including the temporary closure or scale-back of business operations and/or the imposition of either quarantine or remote work or meeting requirements for employees, either by government order or on a voluntary basis. The pandemic may adversely affect our operations, our employees and our employee productivity. It may also impact the ability of our subcontractors, partners, and suppliers to operate and fulfill their contractual obligations, and result in an increase in costs, delays or disruptions in performance. Our employees are working remotely and using various technologies to perform their functions. In reaction to the spread of COVID-19 in the United States, many businesses have instituted social distancing policies, including the closure of offices and worksites and deferring planned business activity. The disruption and volatility in the global and domestic capital markets may increase the cost of capital and limit our ability to access capital. Both the health and economic aspects of the COVID-19 virus are highly fluid and the future course of each is uncertain. For these reasons and other reasons that may come to light if the coronavirus pandemic and associated protective or preventative measures expand, we may experience a material adverse effect on our business operations, revenues and financial condition; however, its ultimate impact is highly uncertain and subject to change. |
NOTE 4 - Transactions with Rela
NOTE 4 - Transactions with Related Persons | 6 Months Ended |
Jun. 30, 2021 | |
Notes | |
NOTE 4 - Transactions with Related Persons | NOTE 4 – Transactions with Related Persons Mr. Michael Mitsunaga, our President and Director, made non-interest-bearing advances to the Company totaling $2,500 and $0 during the three months ended June 30, 2021 and 2019, respectively. Mr. Mitsunaga made non-interest-bearing advances totaling $36,064 and $4,394 during the six months ended June 30, 2021 and 2019, respectively. Mr. Mitsunaga, received reimbursements totaling $10,001 during the three and six months ended June 30, 2021. On April 12, 2021, the Company agreed to issued 5,000,000 shares to Global pursuant to the MSMA. The companies are considered related parties as they share the same CEO and significant shareholder, LionsGate. For additional information see “NOTE 2 – Preferred and Common Stock” above. |
NOTE 5 - Subsequent Events
NOTE 5 - Subsequent Events | 6 Months Ended |
Jun. 30, 2021 | |
Notes | |
NOTE 5 - Subsequent Events | NOTE 5 – Subsequent Events Management has reviewed material events subsequent of the period ended June 30, 2021 and prior to the filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”. On July 8, 2021, the Company issued 3,000,000 shares to Michael Mitsunaga, our President, pursuant to an exclusive licensing agreement Dated December 21, 2020 for use of an IV blood warming system. |
NOTE 1 -Basis of Presentation_2
NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements: Basis of Presentation (Policies) | 6 Months Ended |
Jun. 30, 2021 | |
Policies | |
Basis of Presentation | Basis of Presentation The accompanying unaudited interim consolidated financial statements of Nunzia Pharmaceutical Company (the “ Company The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results may differ from those estimates. The interim financial statements should be read in conjunction with the unaudited financial statements and notes thereto included in the Company’s Annual Report for the year ended December 31, 2020. In the opinion of management, the accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) necessary for the fair presentation of the Company’s financial position as of June 30, 2021, results of operations for the three and six months ended June 30, 2021 and 2020, stockholders equity for the three and six months ended June 30, 2021 and 2020, and cash flows for the six months ended June 30, 2021 and 2020. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year. |
NOTE 1 -Basis of Presentation_3
NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements: Organization (Policies) | 6 Months Ended |
Jun. 30, 2021 | |
Policies | |
Organization | Organization Our Company’s name is Nunzia Pharmaceutical Company. The Company was incorporated on November 12, 1986. On February 1, 2018, the Company amended its Articles of Incorporation to change its name to Nunzia Pharmaceutical Corporation. On October 22, 2017, the Company and Cal-Biotech, Inc. (“ Cal-Biotech MCA MCA Shares LionsGate Prior to the close of the MCA, LionsGate held a majority beneficial ownership interest in the Company and Cal-Biotech. Thus, due to the common control of the Company and Cal-Biotech, pursuant to ASC 805-50-25, “Transactions Between Entities Under Common Control”, the MCA was accounted for as a transfer of the carrying amounts of assets and liabilities under the predecessor value method of accounting. The predecessor values method of accounting requires the receiving entity (i.e., the Company) to report the results of operations as if both entities had been combined as of the beginning of the periods presented. The consolidated financial statements above include both entities’ full results, including the financial statements of Cal-Biotech since inception on February 7, 2018. |
NOTE 1 -Basis of Presentation_4
NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements: Going Concern (Policies) | 6 Months Ended |
Jun. 30, 2021 | |
Policies | |
Going Concern | Going Concern The Company’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as a going concern. As of June 30, 2021, the Company had an accumulated deficit of $(9,372,636) The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. In view of these conditions, the ability of the Company to continue as a going concern is in doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. Historically, the Company has relied upon internally generated funds and funds from the sale of shares of stock, issuance of promissory notes and loans from its shareholders and private investors to finance its operations and growth. Management is planning to raise necessary additional funds for working capital through loans and/or additional sales of its common stock. However, there is no assurance that the Company will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should the Company be unable to raise this amount of capital its operating plans will be limited to the amount of capital that it can access. These financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying financial statements. |
NOTE 1 -Basis of Presentation_5
NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements: Recent accounting pronouncements not yet adopted (Policies) | 6 Months Ended |
Jun. 30, 2021 | |
Policies | |
Recent accounting pronouncements not yet adopted | Recent accounting pronouncements not yet adopted In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes. The guidance removes certain exceptions for recognizing deferred taxes for equity method investments, performing intra period allocation, and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for goodwill and allocating taxes to members of a consolidated group, among others. This guidance is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The transition requirements are dependent upon each amendment within this update and will be applied either prospectively or retrospectively. The adoption of ASU 2019-12 is not expected to have a material impact on the Company’s consolidated financial position, results of operations, or cash flows. |
NOTE 1 -Basis of Presentation_6
NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements: Recently adopted accounting pronouncements (Policies) | 6 Months Ended |
Jun. 30, 2021 | |
Policies | |
Recently adopted accounting pronouncements | Recently adopted accounting pronouncements The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the consolidated financial statements. |
NOTE 1 -Basis of Presentation_7
NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements: Organization (Details) - USD ($) | Dec. 13, 2020 | Feb. 01, 2018 | Jun. 30, 2021 | Aug. 16, 2020 |
Stockholders Equity Reverse Stock Split | 7,000:1 | |||
Merger And Consolidation Agreement | ||||
Shares Unissued | 284,500,000 | 31,650,000 | 31,650,000 | |
Merger And Consolidation Agreement | LionGates Majority Owner Of Cal Biotech | ||||
Shares Unissued | 31,650,000 | |||
Shares Issued In Exchange Of Debt Settlement | 248,270,000 | |||
Debt Settlement | $ 156,657 | |||
Merger And Consolidation Agreement | Cal Biotech - Related And Non Related Parties | ||||
Shares Issued In Exchange Of Debt Settlement | 36,230,000 | |||
Debt Settlement | $ 144,570 |
NOTE 1 -Basis of Presentation_8
NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements: Going Concern (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Details | ||
Retained deficit | $ (9,372,636) | $ (9,350,359) |
NOTE 2 - Preferred and Common_2
NOTE 2 - Preferred and Common Stock (Details) - USD ($) | 6 Months Ended | ||||||
Jun. 30, 2021 | Jun. 07, 2021 | Apr. 26, 2021 | Apr. 12, 2021 | Dec. 31, 2020 | Dec. 13, 2020 | Aug. 16, 2020 | |
Merger And Consolidation Agreement | |||||||
Shares Unissued | 31,650,000 | 284,500,000 | 31,650,000 | ||||
Shares, Issued | 17,750,000 | ||||||
Shares Returned | 9,000,000 | ||||||
Mutual Sales And Marketing Agreement - Global Whole Helath Partners Corp | |||||||
Shares Unissued | 5,000,000 | ||||||
Global WholeHealth Partners Corp | Restricted Stock | |||||||
Shares Unissued | 5,000,000 | ||||||
Investment in related party | $ 5,000 | ||||||
Common Class B | |||||||
Common Stock, Shares, Issued | 51,000 | 51,000 | |||||
Common Stock, Shares, Outstanding | 51,000 | 51,000 | |||||
Common Stock, Voting Rights | The Class B shares are the only shares eligible to vote for Directors. LionsGate holds all Class B common shares | ||||||
Common Stock, Shares Authorized | 100,000 | 100,000 | |||||
Common Class A | |||||||
Common Stock, Shares, Issued | 253,119,578 | 244,369,578 | |||||
Common Stock, Shares, Outstanding | 253,119,578 | 244,369,578 | |||||
Common Stock, Shares Authorized | 1,000,000,000 | 1,000,000,000 | |||||
Common Stock, Shares, Issued | 234,519,578 | ||||||
Common Stock, Shares, Issued | 234,519,578 | ||||||
Preferred Stock | |||||||
Preferred Stock, Par or Stated Value Per Share | $ 1 | ||||||
Preferred Stock, Shares Authorized | 50,000,000 |
NOTE 4 - Transactions with Re_2
NOTE 4 - Transactions with Related Persons (Details) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Apr. 12, 2021 | |
Global WholeHealth Partners Corp | Restricted Stock | |||||
Shares Unissued | 5,000,000 | ||||
Mr.Michael Mitsunaga, President And Director | |||||
Advances From Related Party | $ 2,500 | $ 0 | $ 36,064 | $ 4,394 | |
Payment of reimbursement | $ 10,001 | $ 10,001 |
NOTE 5 - Subsequent Events (Det
NOTE 5 - Subsequent Events (Details) | Jul. 08, 2021shares |
Subsequent Event | Mr.Michael Mitsunaga, President And Director | License Agreement With Michael Mitsunaga | |
Shares, Issued | 3,000,000 |